09 Oct, 2024 Alnylam TTR Investor Day 2024

On October 9, 2024, we hosted a TTR Investor Day to discuss Alnylam’s potential for market leadership in ATTR amyloidosis. The event included presentations from Alnylam’s senior commercial leaders, as well as a leading expert in ATTR amyloidosis.

To view the webcast, click here
To view the presentation, click here

Speakers:

Yvonne Greenstreet, MBChB – Chief Executive Officer
Dr. Yvonne Greenstreet joined Alnylam in 2016 as Chief Operating Officer, was promoted to President and COO in 2020, and was appointed as a Director and Chief Executive Officer in late 2021. Yvonne has more than 25 years of experience in the Biopharmaceutical industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally.

Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer serving on the executive team leading a rapidly growing $16bn division. Prior to Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicines Development and Chief Medical Officer for Europe.

Yvonne trained as a physician and earned her medical degree (MBChB) from The University of Leeds in the UK. She also holds an MBA from INSEAD Business school in France. Dr. Greenstreet serves on the board of directors of The American Funds and previously served on the board of directors of Pacira BioSciences, Inc. and argenx SE. Additionally, she is in the Scientific Advisory Committee of the Bill and Melinda Gates Foundation, a member of the Discovery Council of Harvard Medical School and a member of Biotechnology Industry Organization (BIO) Health Section Governing Board (HSGB).

Dr. Ahmad Masri, M.D., M.S. – Associate Professor of Medicine, Division of Cardiovascular Medicine, Oregon Health & Science University
Dr. Masri heads the Cardiomyopathy Section, the Cardiac Amyloidosis Program, and the Hypertrophic Cardiomyopathy Center at the Oregon Health & Science University in Portland, Oregon, where he is also an Associate Professor of Medicine.

Dr. Masri obtained his medical degree from Jordan University of Science and Technology in Jordan prior to joining the Cleveland Clinic where he completed Internal Medicine Residency training. He later joined the University of Pittsburgh where he completed Cardiology and Cardiac Imaging fellowships, T32 post-doctoral fellowship, and obtained a graduate degree in Epidemiology and Statistics. Dr. Masri leads a multidisciplinary translational, imaging, and clinical research program which focuses on cardiomyopathies.

John Vest, M.D. – SVP, TTR Global Development Lead
Dr. John Vest joined Alnylam in 2015 and is currently Senior Vice President, TTR Global Development Lead. In this role Dr. Vest oversees both the clinical development strategy and clinical trial execution for Alnylam’s innovative RNAi therapeutics targeting transthyretin. He has played an instrumental role in multiple pivotal Phase 3 studies of ONPATTRO and vutrisiran. Before joining Alnylam, he worked in the Cardiovascular Translational Medicine group at Novartis where he played a key clinical role in developing the company’s early stage pipeline of compounds in the cardiovascular space. Prior to his career in industry, Dr. Vest spent over 16 years in the study and practice of medicine. Dr. Vest received his MD from Columbia University where he went on to complete a residency in Internal Medicine and fellowship in Cardiovascular Disease. He subsequently completed sub-specialty training in Clinical Cardiac Electrophysiology at the Brigham and Women’s Hospital before returning to Columbia where he joined the faculty of the Cardiology Division.

Tolga Tanguler – Chief Commercial Officer
Tolga Tanguler joined Alnylam in January 2021 and has over 20 years of global biopharmaceutical experience in a variety of marketing and commercial roles. He has worked across multiple geographies including the U.S., Europe, and emerging markets and in a broad range of small and large disease therapy areas.

Prior to joining Alnylam, Tolga served for two years as Senior Vice President and Head of Alexion U.S., where he led an organization of 700 colleagues across sales, market access, marketing, operations, and patient services. Before Alexion, he spent the majority of his career at Pfizer serving in roles of increasing responsibility, most recently as Regional President, North America for Rare Diseases and prior to that as Global Vice President and Alliance Co-Head, Eliquis, as well as and serving as a country manager of Denmark and Iceland during his tenure.

Tolga received his Bachelor of Science in Finance and Economics from Istanbul University in Turkey and his MBA in Marketing and Supply Chain Management from Michigan State University, as well as a post graduate certificate in Marketing from the University of California, Santa Barbara.

John Kennedy – VP, TTR Franchise Global Commercialization Lead
John Kennedy is Vice President, TTR Franchise Global Commercialization Lead. John brings more than 25 years of experience spanning general management, a range of in-country and global commercial roles, as well as a background in regulatory affairs supporting pre- and post-approval programs.

John joins us from Alexion, where he was Vice President and Business Unit Lead for Alexion’s US Hematology & Nephrology Rare Disease Franchise. In that role, John led business unit strategy, oversaw cross-functional operations and was accountable for financial performance. He oversaw the US launch of what is now a multi-indication flagship brand for Alexion including lifecycle and commercial model evolution, enabling sustained leadership in an evolving competitive landscape.

Prior to Alexion, John spent 20 years at Pfizer where he served in general management roles (Country Manager, Business Unit Lead) and various leadership roles across Marketing, Sales and Account Management. John rose to commercial leadership roles after progressing through a series of global and in-country marketing positions supporting brands including Lipitor (in both US and Global Marketing organizations) within the cardiovascular space, amongst others. Before moving into these commercial roles, John served as a Director of Worldwide Regulatory Strategy with responsibility for pre- and post-approval programs across a range of therapeutic areas.

Mark Soued – SVP, Head of U.S. & TTR Lead
Mark Soued is currently the Senior Vice President, Head of US & TTR Lead at Alnylam. Prior to Alnylam, Mark spent almost 21 years at Pfizer. In his final role before joining Alnylam he served as the Regional President for Pfizer’s North America Hospital Business Unit with responsibility for leading an organization representing ~400 colleagues, >150 products, and generating ~$3B in annual revenues. In this role he also led the negotiation that secured a $5.3B US government contract to purchase 10M courses of Pfizer’s new COVID antiviral, PAXLOVID. Prior to this, Mark served as Pfizer’s Vice President, Global Rare Cardiology Franchise Lead, with responsibility for building a rare cardiology franchise with Vyndaqel/Vyndamax (tafamidis) at its core. Preceding this, Mark served as Pfizer’s US Marketing Lead for Vyndaqel/Vyndamax, where he led the highly successful US launch of the brands that exceeded both Pfizer and Wall Street expectations.

During his time with Pfizer, Mark held multiple additional roles including Oncology Business Unit Lead for Northwestern Europe overseeing Pfizer’s overall oncology business in the Netherlands and Nordics, and Asia-Pacific Regional Marketing Lead with responsibility for launching and growing Pfizer’s oncology portfolio across 13 markets. Mark also served as the Director of Business Operations and Strategy for Pfizer’s Specialty & Oncology Commercial Unit, where he was involved in a broad range of strategic/operational initiatives for the Oncology, Inflammation, Anti-Infectives, and Rare Diseases portfolios. Additionally, Mark held various US marketing roles in neuroscience and anti-infectives, as well as early roles in Corporate Finance.

Before Pfizer, Mark worked in technology and manufacturing, and also founded a technology startup. Mark holds an M.B.A. from the Kellogg School of Management, and a Bachelor of Science in Finance from the University of Colorado. He currently lives in Boston and New York City with his wife, Deb.

Jason Gidelson – VP, U.S. Market Access
Jason Gidelson joined Alnylam in October 2023 as VP, U.S. Market Access. Prior to this role he spent 5 years with Alexion leading its U.S. Market Access team. He brings over 25 years of Market Access experience including 20 years with Wyeth Pharmaceuticals and Pfizer. He has successfully developed U.S. payer and distribution strategies for both Healthcare Provider administered and self-administered medicines in highly competitive specialty and rare disease markets. Jason holds an MBA with a concentration in Finance from Temple University, Philadelphia, PA and a Bachelor of Science Degree in Business Management from Bloomsburg University, Bloomsburg, PA.

Pushkal Garg, M.D. – Chief Medical Officer
Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees all clinical development activities at Alnylam as Chief Medical Officer and Executive Vice President of Development and Medical Affairs.

Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience franchise and oversaw the development of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). Preceding this, Dr. Garg held various roles at Millennium Pharmaceuticals, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.

Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and his M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry. Dr. Garg is a member of the Board of Directors of SQZ Biotechnologies (SQZ).

Jeff Poulton – Chief Financial Officer
Jeff Poulton joined Alnylam as CFO in August 2019. Prior to joining Alnylam, Jeff served as Chief Financial Officer at Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the US.

Between 2003 and December 2017, Jeff held various roles of increasing responsibility at Shire Plc, culminating in his service as Chief Financial Officer and a member of Shire’s Executive Committee and Board of Directors from January 2015 to December 2017. During his tenure at Shire, Jeff also led Shire’s rare disease US, LATAM, and Asia Pacific commercial operations, as well as Shire’s global rare disease business unit. Prior to Shire, Jeff led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corp and PPG Industries. Jeff also served in the United States Navy as a Commissioned Officer.

Jeff holds a BA in Economics from Duke University and an MBA in Finance from the Kelley School of Business at Indiana University. He is a member of the Board of Directors of CervoMed Inc.

Agenda: